LENZ Therapeutics (LENZ) EBT Margin (2025 - 2026)
LENZ Therapeutics (LENZ) reported EBT Margin of 2182.59% for Q1 2026, down 860.08% on a QoQ basis from 287.15% in Q4 2025.
LENZ Therapeutics (LENZ) has 2 years of EBT Margin data on file, last reported at 2182.59% in Q1 2026.
- Quarterly EBT Margin changed N/A year-over-year to 2182.59% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1572.19% (changed N/A YoY) and the FY2025 annual result came in at 1632.5%, changed N/A from the prior year.
- EBT Margin retreated to 2182.59% in Q1 2026 per LENZ's latest filing, from 287.15% in the prior quarter.
- Across five years, EBT Margin topped out at 287.15% in Q4 2025 and bottomed at 2182.59% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -2,182.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,182.59% |
| Dec 31, 2025 | 287.15% |
| Sep 30, 2025 | -133.60% |
| Jun 30, 2025 | -288.24% |